New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to immunotherapy while others don’t.

Researchers from the Garvan Institute of Medical Research and UNSW Sydney have uncovered that less active versions of a gene called NOD2, in combination with radiotherapy or immunotherapy, may help supercharge the immune system’s ability to attack cancer.

The findings, published in the journal Proceedings of the National Academy of Sciences, could pave the way for more personalized and effective immunotherapy treatments against a range of cancers.